OptymEdge Launches First Dedicated Ophthalmology Trial Platform

The newly launched eSource platform allows direct digital patient data capture, replacing traditional, error-prone manual entry systems.

OptymEdge, part of the US-based Emmes Group, has launched the clinical research industry’s first technology platform built exclusively for ophthalmology trials, marking a significant move in specialized clinical research.

The platform, which was soft-launched at ARVO 2025, initially supports Best Corrected Visual Acuity (BCVA) assessments. In the coming phases, it plans to expand its capabilities to cover a range of visual function endpoints.

The launch represents phase one of a broader digital transformation to enhance accuracy, consistency, and efficiency in complex eye care trials.

The newly launched eSource platform allows direct digital patient data capture, replacing traditional, error-prone manual entry systems. It is explicitly designed for ophthalmology and offers guided workflows for BCVA and other visual function assessments, minimizing examiner variability and enhancing data integrity.

The platform integrates seamlessly with existing Electronic Data Capture (EDC) systems, enabling secure and automated data transfer without additional administrative load.

Future rollouts will include an AI-augmented imaging system for trial image analysis and a digital site network map that showcases OptymEdge’s global trial infrastructure.

“For over 30 years, we’ve been at the forefront of BCVA certification in ophthalmic clinical trials. We saw a need to improve data quality, consistency, and efficiency by developing purpose-built technology platforms from the ground up. Our new eSource platform addresses long-standing challenges in manual BCVA data collection and marks a pivotal step in our transformation into a comprehensive ophthalmic research partner,” said Saqib Parkar, Managing Director at OptymEdge.

In the coming months, the company plans to expand its offerings to include reading centre services and a comprehensive global site network to improve trial standardization and provide sponsors with greater visibility and oversight.

Founded in 1977, Emmes is a global clinical research organization (CRO) supporting government, biotech, and academic partners in designing and managing complex clinical trials across therapeutic areas. Emmes has expanded globally with specialized units like OptymEdge for ophthalmology research.

Stay tuned for more such updates on Digital Health News.

Stay tuned for more such updates on Digital Health News